ILM peeling comes of age

Article

Dr Didier Ducournau explains how the technique he invented based on a mistaken assumption has been refined over the last 21 years.

Key Points

Back in 1985, when it was still believed that macular idiopathic epiretinal membrane (ERM) corresponded to a higher reflection from the retinal surface, Dr Didier Ducournau pioneered a technique he has since performed approximately 16,000 times: Internal Limiting Membrane (ILM) peeling.

The light-bulb moment

"I then discovered that I had a higher visibility of the membrane reflection, as the 5° tilted slit illumination highlighted the reflection much more than the 25° fibre illumination. After having removed the attached posterior hyaloid, I then naturally started to remove the ILM, which was presenting a lot of reflection."

And so, the ILM peeling technique was born. Nevertheless, the surgery was still several years away from becoming a first-line treatment.

"Even after I performed that first procedure, I did not begin to remove the ILM systematically," explained Dr Ducournau. "But in 1987 I had a second chance event: I married Yvette, an ophthalmic pathologist. I sent her 56 specimens of removed ILM, and in all of them she found a certain degree of gliosis: astrocytes and Muller cell endfeet, filled with glial filament protein (GFAP). This had never been seen in a normal retina, and so I concluded that the disease was this gliosis: I decided therefore to remove the ILM systematically during ERM surgery."

Understanding the process

It was only much later that Dr Ducournau realized that this astrocytic proliferation - this gliosis - was in fact a beneficial reaction from the retina. "It is the retina's attempt to fight against an oedema," Dr Ducournau clarified. "Yvette explained to me that in neuropathology the astrocytic proliferation appears at the periphery of a chronic ischaemia in order to limit the effect of the oedema and to repair the synapses.

"This means that when we remove a reflection (the gliosed ILM), we are extracting a healing process - the astrocytic proliferation," acknowledged Dr Ducournau, "but we also remove the Muller cell endfeet."

This theory is consistent with the findings of Professor Sebastian Wolf.1

Dr Ducournau believes that this may explain why ILM removal is an effective treatment.

According to Dr Ducournau, ILM removal has the same long-term results whether reflection, caused by astrocytic proliferation, is present or not. "In fact, in cases of macular oedema following retinal vein occlusion (RVO) or Irvine Gass, where the reflection is mostly absent, ILM removal remains an effective solution. This is amazing," he enthused.

Dr Ducournau believes this can be explained by the fact that Muller cell endfeet extraction acts as a trauma, inducing a retinal response: a Muller cell gliosis. Compared with the astrocytic gliosis, which acts only on the inner part of the retina, the Muller cell gliosis has a much stronger effect on the overall thickness of the retina, acting in the same way that, for example, the radial glia act after a trauma of the spinal cord.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
© 2025 MJH Life Sciences

All rights reserved.